Related Experiment Video
Updated: Aug 14, 2026

Extended 78% Hepatectomy in a Mouse Surgical Model
Published on: May 24, 2024
[Drug therapy in chronic liver disease]
1Leberzentrum, Akademisches Lehrkrankenhaus der Universität Tübingen, Städtische Kliniken Esslingen. kp.maier@kliniken-es.de
Abstract:
Treatment of virally induced chronic hepatitis consists of interferons, nucleotide and nucleoside analogues. So far, combination therapies are not superior to a monotherapeutic regimen. If detected early, inherited metabolic diseases (e.g. hereditary hemochromatosis, M. Wilson) can be successefuly treated, leading to a normal life expectancy of the patients. In contrary treatment of cholestatic chronic liver disease, especially of PSC, is far from being satisfying, due to our very limited knowledge of the etiology of this diseases. The same holds true for the therapy of NASH. Weight reduction and treatment of the often underlying diabetes are therapeutic cornerstones in the moment. On the other hand, immuosuppression, some times life-long, remains a (highly successful) treatment option in cases of proven autoimmune-hepatitis.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Drug Therapy
Antianxiety Medications
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chronic Pancreatitis II: Collaborative Care
Assessment: